Abstract
A total of 127 patients with involutional osteoporosis were randomly divided into two groups. The elcatonin group consisted of 67 patients who received 20 units of elcatonin per week administered intramuscularly, together with 0.6g calcium lactate (100mg as calcium) given orally three times daily for 24 weeks. The other 60 patients were assigned to a control group receiving 0.6g calcium lactate orally three times daily. Forty patients were withdrawn from the study treatment or dropped out during the study. The other 87 patients (consisting of 45 in the elcatonin group, and 42 in the control group) were measured for lumbar vertebral bone mineral density (BMD) using dual-energy X-ray absorptiometry (DXA). The BMD was increased significantly (P < 0.05) by 1.87 ± 0.79% (mean ± standard error) in the elcatonin group and decreased by 0.61 ± 0.93% in the control group at the end of the study. The difference between the two groups was statistically significant (P < 0.05). The results of the present study demonstrated that elcatonin increases the BMD in patients with involutional osteoporosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
